A citation-based method for searching scientific literature

R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp Clin Endocrinol Diabetes 2005
Times Cited: 39







List of co-cited articles
449 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
169
74


A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz, Orville Kolterman. Diabetes Care 2006
95
48


Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
Robert E Ratner, Laura L Want, Mark S Fineman, Maggie J Velte, James A Ruggles, Alan Gottlieb, Christian Weyer, Orville G Kolterman. Diabetes Technol Ther 2002
100
23


Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
89
23

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Priscilla A Hollander, Philip Levy, Mark S Fineman, David G Maggs, Larry Z Shen, Susan A Strobel, Christian Weyer, Orville G Kolterman. Diabetes Care 2003
190
20

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
Priscilla Hollander, David G Maggs, James A Ruggles, Mark Fineman, Larry Shen, Orville G Kolterman, Christian Weyer. Obes Res 2004
104
20

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
David G Marrero, John Crean, Bei Zhang, Terrie Kellmeyer, Maurice Gloster, Kathrin Herrmann, Richard Rubin, Naomi Fineberg, Orville Kolterman. Diabetes Care 2007
30
26

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Christian Weyer, Alan Gottlieb, Dennis D Kim, Karen Lutz, Sherwyn Schwartz, Maria Gutierrez, Yan Wang, James A Ruggles, Orville G Kolterman, David G Maggs. Diabetes Care 2003
61
17

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
P Hollander, R Ratner, M Fineman, S Strobel, L Shen, D Maggs, O Kolterman, C Weyer. Diabetes Obes Metab 2003
47
17

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
984
17

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
M S Fineman, J E Koda, L Z Shen, S A Strobel, D G Maggs, C Weyer, O G Kolterman. Metabolism 2002
80
17

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing,[...]. PLoS One 2008
53
17

The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. Basic Clin Pharmacol Toxicol 2009
33
21

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
66
17

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
117
17


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
796
15

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
844
15

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
I Chapman, B Parker, S Doran, C Feinle-Bisset, J Wishart, S Strobel, Y Wang, C Burns, C Lush, C Weyer,[...]. Diabetologia 2005
119
15

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
S A Amiel, S R Heller, I A Macdonald, S L Schwartz, L J Klaff, J A Ruggles, C Weyer, O G Kolterman, D G Maggs. Diabetes Obes Metab 2005
16
37

Pancreatic polypeptide reduces appetite and food intake in humans.
R L Batterham, C W Le Roux, M A Cohen, A J Park, S M Ellis, M Patterson, G S Frost, M A Ghatei, S R Bloom. J Clin Endocrinol Metab 2003
281
15

Gut hormone PYY(3-36) physiologically inhibits food intake.
Rachel L Batterham, Michael A Cowley, Caroline J Small, Herbert Herzog, Mark A Cohen, Catherine L Dakin, Alison M Wren, Audrey E Brynes, Malcolm J Low, Mohammad A Ghatei,[...]. Nature 2002
15

The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Rubina A Heptulla, Luisa M Rodriguez, Lisa Bomgaars, Morey W Haymond. Diabetes 2005
55
15

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Jill Hamilton, Elizabeth Cummings, Vera Zdravkovic, Diane Finegood, Denis Daneman. Diabetes Care 2003
99
15


The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
Laurent Meyer, Philip Bohme, Irene Delbachian, Philippe Lehert, Nathalie Cugnardey, Pierre Drouin, Bruno Guerci. Diabetes Care 2002
54
15

Effect of pioglitazone therapy in lean type 1 diabetes mellitus.
R Bhat, A Bhansali, S Bhadada, R Sialy. Diabetes Res Clin Pract 2007
29
20

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
86
15

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
111
15

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
156
15

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
99
15

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
94
15

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
66
15

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
68
15


Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
Antonio Ceriello, Ludovica Piconi, Lisa Quagliaro, Yan Wang, Catherine A Schnabel, James A Ruggles, Maurice A Gloster, David G Maggs, Christian Weyer. Diabetes Care 2005
41
12

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
M Samsom, L A Szarka, M Camilleri, A Vella, A R Zinsmeister, R A Rizza. Am J Physiol Gastrointest Liver Physiol 2000
83
12


Properties of pramlintide and insulin upon mixing.
Christian Weyer, Mark S Fineman, Susan Strobel, Larry Shen, Joann Data, Orville G Kolterman, Mario F Sylvestri. Am J Health Syst Pharm 2005
26
19

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
M F Kong, P King, I A Macdonald, T A Stubbs, A C Perkins, P E Blackshaw, C Moyses, R B Tattersall. Diabetologia 1997
85
12


Characterization of the effects of pancreatic polypeptide in the regulation of energy balance.
Akihiro Asakawa, Akio Inui, Hideki Yuzuriha, Naohiko Ueno, Goro Katsuura, Mineko Fujimiya, Masayuki A Fujino, Akira Niijima, Michael M Meguid, Masato Kasuga. Gastroenterology 2003
208
12

Central nervous system control of food intake.
M W Schwartz, S C Woods, D Porte, R J Seeley, D G Baskin. Nature 2000
12

Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake.
Caroline R Abbott, Caroline J Small, Adam R Kennedy, Nicola M Neary, Arshia Sajedi, Mohammad A Ghatei, Stephen R Bloom. Brain Res 2005
116
12

Critical role for peptide YY in protein-mediated satiation and body-weight regulation.
Rachel L Batterham, Helen Heffron, Saloni Kapoor, Joanna E Chivers, Keval Chandarana, Herbert Herzog, Carel W Le Roux, E Louise Thomas, Jimmy D Bell, Dominic J Withers. Cell Metab 2006
352
12

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.
Katie Wynne, Adrian J Park, Caroline J Small, Michael Patterson, Sandra M Ellis, Kevin G Murphy, Alison M Wren, Gary S Frost, Karim Meeran, Mohammad A Ghatei,[...]. Diabetes 2005
244
12



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.